Research programme: collagen inhibitors - AvidexAlternative Names: ReaDex
Latest Information Update: 20 Jun 2006
At a glance
- Originator Avidex
- Mechanism of Action Collagen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 20 Jun 2006 No development reported - Preclinical for Rheumatoid arthritis in United Kingdom (unspecified route)
- 24 Feb 2004 Preclinical trials in Rheumatoid arthritis in United Kingdom (unspecified route)